Kamada: What the Inhaled AAT Halt Changes in Earnings, R&D, and the Thesis
The InnovAATe halt did not just remove optionality. It also made 2025 R&D look cleaner than it really was, because Kamada offset the line with a one-time $3 million payment while $2.6 million of closeout costs still sat inside it. That is why 2026 should be read less as a year of savings already captured, and more as a reset year in which capital allocation will matter more after the late-stage internal program fell away.
What This Follow-up Is Isolating
The main article already argued that Kamada returned to growth, but that 2026 will decide whether this is growth that produces high-quality cash. This follow-up isolates only the Inhaled AAT point, because three different changes are being mixed into one line item here: damage to pipeline optionality, a one-time offset that cleans up the 2025 R&D line, and a real change in how 2026 capital allocation should be read.
To read the story correctly, three facts have to be held together at once:
- The trial was halted because efficacy was unlikely, not because of safety. In December 2025 the DSMB concluded that the InnovAATe trial was unlikely to show statistical significance on its primary endpoint, FEV1, and the company discontinued the study.
- The 2025 R&D line was partly cleaned up by a one-time offset. Kamada received a non-refundable $3 million payment under an exclusivity letter tied to a possible out-licensing of Inhaled AAT distribution rights, and after the trial halt that payment was recorded as an offset to the program's R&D expenses.
- The real savings had barely arrived yet in 2025. In that same line, the company also recorded $2.6 million of closeout costs, so 2025 was a year of mixing program termination with a one-time accounting cleanup, not a clean new cost base.
That chart is the core of the read. The third number is not a company-reported figure but simple arithmetic from the note disclosure: $12.995 million reported plus the $3 million offset. That is why the reported drop in R&D from $15.2 million to $13.0 million looks cleaner than the underlying economics.
The 2025 R&D Decline Was More Presentation Than Savings Already Captured
Item 5 shows a 14.5% decline in R&D expense, from $15.2 million in 2024 to $13.0 million in 2025, and links it to timing changes in development projects, including the InnovAATe halt. That is accurate at the reporting level, but it is not yet enough at the earnings-quality level.
The detailed R&D table shows the Inhaled AAT line falling to $3.0 million from $6.889 million. On first read that looks like a sharp saving. In practice, two forces were moving in opposite directions inside that same line: $2.6 million of closeout costs on one side, and a one-time $3 million offset on the other. In other words, almost the entire reported 2025 Inhaled AAT line was effectively closeout cost, after a one-time offset erased a large part of the spend.
On simple arithmetic, if the $3 million offset is added back, the 2025 Inhaled AAT line would have been around $6.0 million, not far from the $6.889 million recorded in 2024. The same logic applies to total R&D: without the offset, 2025 R&D would have been about $16.0 million, slightly above 2024 rather than below it. The revenue ratio also looks different on that basis: 7.2% as reported, versus roughly 8.9% after adding the offset back, compared with 9.4% in 2024.
| View | 2024 | 2025 | What it means |
|---|---|---|---|
| Reported R&D | $15.185 million | $12.995 million | The headline looks like a sharp decline |
| 2025 R&D after adding back the offset | - | about $15.995 million | The underlying 2025 economics look much closer to 2024 |
| Reported Inhaled AAT line | $6.889 million | $3.0 million | The drop looks too dramatic on first read |
| 2025 Inhaled AAT after adding back the offset | - | about $6.0 million | The real 2025 saving was much smaller |
That leads to an important conclusion: the Inhaled AAT halt changed 2025 earnings quality less through operating savings already realized, and more through a mix of closeout costs and a one-time payment. That means 2025 is not yet a year from which a clean forward R&D run-rate can be taken.
That second chart sharpens another point. Even after the drop in the Inhaled AAT line, Kamada's R&D base still consisted mainly of salary, facility allocation, and general overhead. The meaning of the halt is therefore not an automatic shift to a life-sciences company with no meaningful R&D, but a shift to one with somewhat lower R&D and far less internal optionality.
What Is Actually Left in the Development Pipeline After InnovAATe
At the thesis level, the InnovAATe halt does something deeper than reduce one expense line. It removes Kamada's most advanced internal development program.
The company describes Inhaled AAT as an effort to build an alternative to standard IV treatment for AATD patients, with targeted pulmonary delivery and better convenience. After earlier studies that did not suffice for approval, InnovAATe was the global Phase 3 program under FDA and EMA guidance. In December 2025 the DSMB concluded that the trial was unlikely to show significance on FEV1, and the company discontinued it. Kamada also states explicitly that the decision was not related to safety.
From there, the map changes quickly:
- With PARI, the company says it is in the process of terminating the agreements.
- With the outside clinical-services provider, it says it is negotiating the closeout work and the termination of the agreement once that work is completed.
- At the broader risk level, the company now says that following the halt, its potential investigational products are at early stages of development.
What remains is a much smaller and more cautious pipeline. rhAAT still exists, but the company states clearly that it is seeking a strategic partner for further development and does not plan to continue the program independently. Alongside that, only two early-stage plasma-derived programs remain: plasma-based eye drops in pre-clinical evaluation, and anti-tuberculosis IgG, for which in-vivo work is planned during 2026. Here too management sets a clear discipline: advance only to proof-of-concept, and then decide whether to continue internally, partner, or out-license.
| Program | Status at the end of 2025 | What it means for the thesis |
|---|---|---|
| Inhaled AAT | Phase 3 halted after futility, with closeout still underway | The main internal option is off the table |
| rhAAT | The company is seeking a partner, not developing it alone | Upside remains, but only through a partner |
| Plasma-based eye drops | Pre-clinical | Too early to carry the development thesis |
| Anti-tuberculosis IgG | In-vivo planned for 2026 | Still a proof-of-concept layer, not a near-term value engine |
The accounting-judgment note matters here just as much as the pipeline description itself. Kamada states that development costs are generally expensed until strict capitalization criteria are met, and that those conditions are usually not satisfied before regulatory approvals. It also states, for inventory designated for R&D activities, that recognition before completion of a Phase 3 trial requires probable future economic benefit. That has a double implication: Kamada is not coming into this halt with an inflated development asset sitting on the balance sheet, but the real damage passes straight into the forward thesis, because what is being removed here is not a balance-sheet line that can be debated away, but a layer of future optionality.
What This Changes for 2026 and for Capital Allocation
This transition changes 2026 in two separate layers, and they should not be blended together.
The first is the comparison layer. In 2026, the R&D line may look cleaner simply because 2025 included both $2.6 million of closeout costs and a one-time $3 million offset inside the same line. That is a mechanical comparison effect. It says something about the base period, not necessarily about the quality of the new earnings stream.
The second is the allocation layer. Here the change is more real. Kamada states that its primary uses of cash are working capital, R&D, capital expenditures, and acquisitions of products, product candidates, and assets. At the same time, it already expects capital expenditures to rise in coming years because of the new filling line in Beit Kama and the transfer of HEPAGAM B, VARIZIG, and WINRHO SDF manufacturing. At year-end 2025 it held $75.5 million of cash and cash equivalents, and it generated $25.5 million of operating cash flow.
So after the Inhaled AAT halt, the 2026 question is no longer whether Kamada keeps funding a late-stage internal lung program. It is a different question: where the relatively freed-up dollars now go. Do they remain in earnings and cash, do they get absorbed by industrial capex and expansion, do they get redirected into business development and acquisitions, or does management eventually rebuild a larger development layer in another form?
That is exactly why the halt changes the thesis, not only the R&D line. It makes Kamada even more commercial and industrial, but also less internally optional. Anyone reading 2026 will have to separate two questions:
- Does earnings quality improve because one-time noise disappears?
- Does allocation quality improve because management spends less on R&D that is not progressing and more on engines that can already earn a return?
If the relative saving stays on the balance sheet or is redeployed carefully into areas with better visibility, the halt may look like a healthy reset in hindsight. If it is simply replaced by a new round of spending without clear milestones, then 2026 will look like a year in which Kamada lost a large option without gaining much true simplification in return.
Bottom Line
The InnovAATe halt did not clean up 2025. It mainly distorted the easy first read of it. The reported R&D line fell to $13.0 million, but that decline includes a one-time $3 million offset against $2.6 million of closeout costs, so the true 2025 expense base sits much closer to 2024 than the headline implies.
The larger hit is forward-looking. Kamada still has a commercial business, industrial capex, and tangible growth engines, but it now has a much earlier and more cautious internal pipeline. rhAAT already depends on a partner, the other two programs are only proof-of-concept layers, and the only internal Phase 3 program is gone.
That is why the right 2026 read is not "R&D is down, so earnings are cleaner." The right read is different: 2026 is a reset year in which Kamada has to show that the Inhaled AAT halt can translate into a better mix of earnings quality, R&D discipline, and capital allocation. That may produce a more readable commercial company, but also one with less internal dream value. From here, whatever replaces that dream has to show a real return on capital.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.